MedTrace Logo

Caffeic Acid Combining High-dose Dexamethasone in Management of ITP

NCT02556814 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2020-03-20

No results posted yet for this study

Summary

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of caffeic acid tablets combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

Conditions

Interventions

DRUG

Caffeic acid tablets

Oral administration of caffeic acid tablets 0.3g three times per day for 3 months

DRUG

Dexamethasone

Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.

DRUG

placebo

Oral administration of placebo tablets 0.3g three times per day for 3 months

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Ming Hou, MD, PhD · Shandong University Qilu Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2018-03-31
Completion
2018-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02556814 on ClinicalTrials.gov